SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.15+2.8%12:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andrew H who wrote (3929)9/26/1997 9:54:00 PM
From: Turbo Lawyer   of 17367
 
I am unworthy in comparison to the excellent thoughts which have been set forth here on this thread re stats and science. From my perspective at this point I think another test is going to be if/when any big name analyst/investment firm gives its support to Xoma's pipeline(s). (other than the current newletter recs). I also wonder if any big name pharmaceuticals are connecting with XOMA to discuss promotion of Neuprex - I would hope there are discussions going on as we speak. It has been established that Neuprex is safe - Neuprex work extremely well at Phase II (re meningoccocemia) , it's allowed to continue to Phase III - with that said, I would like to open the thread to discussions of the possibility of XOMA getting some support ($$$ or otherwise) from some heavy hitters and/or getting a strong rec from an investment firm and/or reputable analyst. I provide IMMUNEX as an example.

December 12, 1996 (Investors Business Daily)

"..... IMMUNEX CORP. leapt 2 3/8 to 18 3/4 on 10 times its average volume. Donaldson Lufkin & Jenrette Securities Corp. began coverage with a ''buy'' rating. The firm called the company's product pipeline ''exceptionally strong.'' Immunex develops drugs to boost the body's ability to fight cancer, arthritis and other auto-immune diseases.."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext